ClinicalTrials.gg
TerminatedNCT02244489Updated Feb 1, 2019

Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

A Phase 1 interventional study of Momelotinib (MMB) and Capecitabine in Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Sierra Oncology LLC - a GSK company. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-01.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Sierra Oncology LLC - a GSK company (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2017, 9 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the safety, tolerability, and define the maximum tolerated dose (MTD) of momelotinib (MMB) combined with capecitabine and oxaliplatin in adults with relapsed/refractory metastatic pancreatic ductal adenocarcinoma.

02

Conditions studied

  • Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

Browse trials for

03

In context

Lead sponsor

Sierra Oncology LLC - a GSK company is the lead sponsor of 19 studies on the registry; none are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.

First submitted before Sierra Oncology LLC became part of GlaxoSmithKline.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • pancreatic adenocarcinoma
  • Received 1 prior chemotherapy regimen for metastatic pancreatic ductal adenocarcinoma (not including and/or adjuvant therapy)
  • per v1.1
  • Adequate organ function defined as

    • (AST) and alanine transaminase (ALT) ≤ 3 x (ULN) OR ≤ 5 x ULN if liver metastases are present; total conjugated ≤ 2 x ULN
    • (ANC) ≥1500 cells/mm\^3, ≥100,000 cells/mm\^3, ≥ 9.0 g/dL
    • (CrCl) > 50 ml/min as calculated by the Cockroft-Gault method
  • (ECOG) Performance Status of 0 or 1

Key Exclusion Criteria:

  • Received more than 1 for metastatic pancreatic ductal adenocarcinoma
  • Major surgery within 21 days of first dose of study drug
  • Minor surgical procedure(s) within 7 days of enrollment or not yet recovered from prior minor surgery (placement of central venous access device, fine needle aspiration, or endoscopic biliary stent ≥ 1 day before enrollment is acceptable)
  • Chemotherapy, immunotherapy, biologics, and/or therapy within 21 days prior to first dose of study drug
  • Known positive status for , chronic active or acute viral hepatitis A, B, or C infection, or or C carrier
  • Known dihydropyrimidine dehydrogenase deficiency
  • Peripheral neuropathy ≥ Grade 2
  • Any condition that impairs gastrointestinal absorption of drug
  • Known or suspected brain or central nervous system metastases
  • Diagnosis of pancreatic islet neoplasm, acinar cell carcinoma, non-adenocarcinoma, adenocarcinoma originating from the biliary tree or cystadenocarcinoma
  • External biliary drain
  • Documented myocardial infarction or unstable/uncontrolled cardiac disease within 6 months of enrollment

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Momelotinib (MMB)+capecitabine

    Participants will receive momelotinib (MMB)+capecitabine at varying dose levels to determine the MTD for momelotinib (MMB) and capecitabine.

    Drug: Momelotinib (MMB) · Drug: Capecitabine

  • Experimental
    Momelotinib (MMB)+capecitabine+oxaliplatin

    Upon reaching the MTD for momelotinib (MMB) and capecitabine or if no MTD is reached, participants will receive momelotinib (MMB)+capecitabine at the MTD plus oxaliplatin at varying dose levels to determine the MTD of combination capecitabine, momelotinib (MMB), and oxaliplatin.

    Drug: Momelotinib (MMB) · Drug: Capecitabine · Drug: Oxaliplatin

Interventions

  • Momelotinib (MMB) tablet(s) administered orally once or twice daily

    Also known as: GS-0387, CYT387

  • Capecitabine tablet(s) administered orally twice daily for 14 days, followed by 7 days off, until the end of treatment

  • Oxaliplatin administered intravenously over 120 minutes or as per institutional standard of care on Day 1 of each 21-day cycle.

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities

    Dose limiting toxicities refer to toxicities experienced during the first 21 days of treatment that have been judged to be clinically significant and at least possibly related to study treatment.

    Time frame: Up to 21 days

  2. Incidence of adverse events, assessment of clinical laboratory test findings, physical examination, 12-lead electrocardiogram (ECG), and vital signs measurements

    This composite endpoint will measure the safety profile of momelotinib.

    Time frame: Up to 2 years

Secondary outcomes

  1. Overall response rate

    Overall response rate (ORR) is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) as assessed by the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.

    Time frame: Up to 2 years

  2. Overall survival

    Overall survival (OS) is defined as the interval from first dose date of study drug to death from any cause.

    Time frame: Up to 2 years

  3. Progression-free survival

    Progression-free survival (PFS) is defined as the interval from first dose date of study drug to the earlier of the first documentation of definitive disease progression or death from any cause; definitive disease progression is progression based on RECIST criteria v1.1.

    Time frame: Up to 2 years

  4. Pharmacokinetic (PK) profile of momelotinib (MMB)

    This composite endpoint will measure the plasma PK profile of momelotinib (MMB). The following parameters will be measured, where applicable: * Cmax: maximum observed concentration of drug in plasma * Ctau: observed drug concentration at the end of the dosing interval * AUCtau: concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval)

    Time frame: Predose and postdose on Day 15

07

Study locations

4 sites
  • Scottsdale Healthcare Research Institute
    Scottsdale, Arizona 85258, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2014 to primary completion in Mar 2017, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2014
First posted
Sep 19, 2014
StartActual
Nov 5, 2014
Primary completionActual
Mar 8, 2017
CompletionActual
Apr 5, 2017
Last update
Feb 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02244489
Responsible party
Sponsor
First posted
Sep 19, 2014
Start date
Nov 5, 2014
Primary completion
Mar 8, 2017
Completion
Apr 5, 2017
Last update
Feb 1, 2019

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Momelotinib · Capecitabine

Start the discussion